At a glance
- Originator Nihon Schering
- Class Anti-ischaemics
- Mechanism of Action Sodium hydrogen antiporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Myocardial infarction; Reperfusion injury
Most Recent Events
- 27 Mar 2000 Mitsui Pharmaceuticals has been acquired by Schering AG
- 27 Sep 1999 Preclinical development for Myocardial infarction in Japan (Unknown route)
- 27 Sep 1999 Preclinical development for Reperfusion injury in Japan (Unknown route)